about
Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma.Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphomaExpression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples.A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.Stem Cell-based Therapies for Sepsis.Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopesCatastrophic tumour lysis syndrome following single dose of imatinib.Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.Myeloid and lymphoid neoplasm with FGFR1 abnormality.A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphomaMulti-organ involvement with crystal-storing histiocytosisValproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activityTumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphomaThe Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationTreatment of acute promyelocytic leukaemia in the Jehovah's Witness populationSimple, rapid and inexpensive typing of common HLA class I alleles for immunological studiesBiology and therapy of primary mediastinal B-cell lymphoma: current status and future directionsThe tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphomaOutcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceDesigning optimal prognostic models for diffuse large B-cell lymphoma
P50
Q34212528-89D367A3-7394-4071-942F-2E691E4A4D2CQ34384556-5F34EAE1-1078-4433-AEFF-38F41AC58519Q35723986-0347F539-6EB6-4811-A1E7-E0B1253391C5Q36457849-5DE5FEE6-D54A-4240-8206-7A77067A0716Q38403375-63DBC7DA-9509-4CD9-94B5-E672F517E67DQ38965273-A1C0ED47-2CE3-44E3-B18D-0CA60E49CC07Q40066691-16F5DAD7-7962-413A-B1E5-943BD4A847ECQ40338899-080BF63E-7EC6-44B0-87B1-E2B066ACBB6CQ40573262-D8D868DC-0132-46DE-A5E4-82540CC92E50Q42027228-469544EC-464C-4BB4-8487-F16CC6CF4F5BQ46207564-044AA246-E5B1-4EA1-82B8-A71D02271DF1Q49961097-283771B8-7E7B-4449-AAAA-BEDA62673F37Q50545382-41374C78-C93A-47C2-85E2-4AA5FAB5FA83Q54781221-98F4E1CF-1E31-4AEF-961E-03CAD211CE74Q55299986-1BD63DD4-4E47-40CF-B766-8033F835B9E8Q58582706-6261A266-53BC-4EA7-85D3-8C4347F1316DQ81135211-6A8210EB-CD66-4620-A938-3F0204A9DF52Q82583837-ACCDCE2A-A2F7-4DA8-9E6F-65F3CFAB8914Q83165991-B484A9FF-F193-411F-A60C-6D5A18FE1D18Q83996560-5A88A0C2-384A-4DE6-B47C-9A76EF408FE2Q84534483-605324C3-CE0A-4252-BC46-F1070F6A2453Q90407229-6F2A942F-3204-4F3C-859C-06A9C21F0C46Q91444187-D04892B5-6940-4161-B3F8-F3EBDB0C50E0Q92847525-0185183E-DF53-41C0-B560-D9DF18E24F68Q93007162-938D6B7B-C949-4D54-9C5C-834F27F787EEQ93134323-2727817D-780C-4208-B227-003F1C16DDA1
P50
description
researcher ORCID ID = 0000-0002-9009-9934
@en
wetenschapper
@nl
name
Colm Keane
@ast
Colm Keane
@en
Colm Keane
@es
Colm Keane
@nl
type
label
Colm Keane
@ast
Colm Keane
@en
Colm Keane
@es
Colm Keane
@nl
prefLabel
Colm Keane
@ast
Colm Keane
@en
Colm Keane
@es
Colm Keane
@nl
P106
P31
P496
0000-0002-9009-9934